Cas:866849-23-2 5-(4-methylpiperazin-1-yl)-2,3-dihydroinden-1-one manufacturer & supplier

We serve Chemical Name:5-(4-methylpiperazin-1-yl)-2,3-dihydroinden-1-one CAS:866849-23-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-(4-methylpiperazin-1-yl)-2,3-dihydroinden-1-one

Chemical Name:5-(4-methylpiperazin-1-yl)-2,3-dihydroinden-1-one
CAS.NO:866849-23-2
Synonyms:5-(4-methylpiperazin-1-yl)-indan-1-one
Molecular Formula:C14H18N2O
Molecular Weight:230.30600
HS Code:2933599090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:23.55000
Exact Mass:230.14200
LogP:1.57020

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-(4-methylpiperazin-1-yl)-indan-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-methylpiperazin-1-yl)-indan-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-methylpiperazin-1-yl)-indan-1-one Use and application,5-(4-methylpiperazin-1-yl)-indan-1-one technical grade,usp/ep/jp grade.


Related News: Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients” 2-bromo-N-(1,3-thiazol-2-yl)acetamide manufacturers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 3-[4-(trifluoromethyl)phenyl]pyridine suppliers Orchard’s decision is suggestive of the difficulty drugmakers can face in turning complex, but promising rare disease treatments into a sustainable business. The termination wasn’t unexpected; Orchard said last May it was reducing staff and reordering its priorities, reducing investment in OTL-101 as a result. 2,4-O-(3,4-Dimethylbenzylidene)-D-sorbitol vendor & factory.